Rifkin-Zybutz, R;
Erridge, S;
Holvey, C;
Coomber, R;
Gaffney, J;
Lawn, W;
Barros, D;
Bhoskar, U;
Mwimba, G;
Praveen, K;
et al.
Rifkin-Zybutz, R; Erridge, S; Holvey, C; Coomber, R; Gaffney, J; Lawn, W; Barros, D; Bhoskar, U; Mwimba, G; Praveen, K; Symeon, C; Sachdeva-Mohan, S; Rucker, JJ; Sodergren, MH
(2023)
Clinical outcome data of anxiety patients treated with cannabis-based medicinal products in the United Kingdom: a cohort study from the UK Medical Cannabis Registry.
Psychopharmacology (Berl), 240 (8).
pp. 1735-1745.
ISSN 1432-2072
https://doi.org/10.1007/s00213-023-06399-3
SGUL Authors: Coomber, Ross Steven
Abstract
RATIONALE: Cannabis-based medicinal products (CBMPs) have been identified as novel therapeutics for generalised anxiety disorder (GAD) based on pre-clinical models; however, there is a paucity of high-quality evidence on their effectiveness and safety. OBJECTIVES: This study aimed to evaluate the clinical outcomes of patients with GAD treated with dried flower, oil-based preparations, or a combination of both CBMPs. METHODS: A prospective cohort study of patients with GAD (n = 302) enrolled in the UK Medical Cannabis Registry prescribed oil or flower-based CBMPs was performed. Primary outcomes were changes in generalised anxiety disorder-7 (GAD-7) questionnaires at 1, 3, and 6 months compared to baseline. Secondary outcomes were single-item sleep quality scale (SQS) and health-related quality of life index (EQ-5D-5L) questionnaires at the same time points. These changes were assessed by paired t-tests. Adverse events were assessed in line with CTCAE (Common Terminology Criteria for Adverse Events) v4.0. RESULTS: Improvements in anxiety, sleep quality and quality of life were observed at each time point (p < 0.001). Patients receiving CBMPs had improvements in GAD-7 at all time points (1 month: difference -5.3 (95% CI -4.6 to -6.1), 3 months: difference -5.5 (95% CI -4.7 to -6.4), 6 months: difference -4.5 (95% CI -3.2 to -5.7)). Thirty-nine participants (12.9%) reported 269 adverse events in the follow-up period. CONCLUSIONS: Prescription of CBMPs in those with GAD is associated with clinically significant improvements in anxiety with an acceptable safety profile in a real-world setting. Randomised trials are required as a next step to investigate the efficacy of CBMPs.
Item Type: |
Article
|
Additional Information: |
© The Author(s) 2023
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. |
Keywords: |
Anxiety, Cannabidiol, Cannabis, Generalised anxiety disorder, Tetrahydrocannabinol, Cannabis, Cannabidiol, Tetrahydrocannabinol, Anxiety, Generalised anxiety disorder, 11 Medical and Health Sciences, 17 Psychology and Cognitive Sciences, Psychiatry |
SGUL Research Institute / Research Centre: |
Academic Structure > Institute of Medical & Biomedical Education (IMBE) Academic Structure > Institute of Medical & Biomedical Education (IMBE) > Centre for Clinical Education (INMECE ) |
Journal or Publication Title: |
Psychopharmacology (Berl) |
ISSN: |
1432-2072 |
Language: |
eng |
Dates: |
Date | Event |
---|
August 2023 | Published | 14 June 2023 | Published Online | 1 June 2023 | Accepted |
|
Publisher License: |
Creative Commons: Attribution 4.0 |
Projects: |
|
PubMed ID: |
37314478 |
Web of Science ID: |
WOS:001007656000003 |
![](http://static.pubmed.gov/portal/portal3rc.fcgi/2745237/img/27842) |
Go to PubMed abstract |
URI: |
https://openaccess.sgul.ac.uk/id/eprint/115543 |
Publisher's version: |
https://doi.org/10.1007/s00213-023-06399-3 |
Statistics
Item downloaded times since 14 Jul 2023.
Actions (login required)
![Edit Item](/style/images/action_view.png) |
Edit Item |